Investing Online

[lana2b]

ALL of them in a current uptrend
PFE- healthy profit takien, bouncing off ma50
STZ- basing
WWW-off the support and base and ma 20, no resist ahead good V and little resistance ahead, notice how the volume repeat the PR pattern
NVEC- MA 20 rigth above MA 50, but looks like found support , can be very nice and quick profit
looking at %R may retreate for one day and cont. up
RBN- channeling, off the bottom
GOL- channeling, off the bottom and bounced off ma200
ENH- nice consolidation before next leg up (IMHO)
DVA- channeling, at support and trend line at 55.85, dogi, green candle, dogi-Mmm- not sure, didnt fill the GAP,

GLTO

lana

[lana2b]

NVS- channeling ,at support, but may break down and recover
GMR - not in uptrend. double bottomed at support, close above MA200, MA20 kissing MA200, all indicators turning up-if continue up will be nice

DO your DD , any opinion appreciated

lana

[lana2b]

NVS had nice comments last friday

Sales of diabetes drugs could soar from $12 billion now to $26 billion in 2011, according to investment research firm Sanford C. Bernstein. At that point diabetes drugs could generate more sales than cholesterol-lowering pills do now. "It is a big growth area, no question," says Novartis (nyse: NVS - news - people ) Chief Executive Daniel Vasella, whose firm has one diabetes drug on the market and hopes to receive approval for a second one later this year

Galvus / Novartis (nyse: NVS - news - people )

One of a new drug class aimed at lowering blood sugar without side effects such as weight gain, fluid retention or excessively low blood sugar.

Possible approval: late 2006.

ZURICH (Dow Jones)--Swiss drugmakers Roche Holding AG (RHHBY) and Novartis AG (NVS) will both report healthy growth in third-quarter sales next week, analysts said. Basel-based Roche will report a 16% increase in sales to CHF10.24 billion ($8.05 billion), led by a 19% increase in revenue to CHF8.05 billion at its flagship pharmaceutical unit, according to an average estimate of 12 analysts polled by Dow Jones Newswires.
"In the third quarter we expect another strong performance for the pharmaceutical division driven mainly by the Genentech products on a global basis, as well as the first-time contribution from Lucentis in the U.S. and a strong performance from Tamiflu," analysts at Credit Suisse said in a note to investors.
Eye disease treatment Lucentis and cancer drugs Avastin, Herceptin and Rituxan were developed by Genentech Inc. (DNA), a U.S. biotechnology company majority owned by Roche. Genentech is selling these drugs in the U.S., and Roche consolidates the Genentech sales. With the exception of Lucentis, which is sold by Novartis AG (NVS), Roche is selling the drugs outside the U.S.

Leading off for the drug giants, Dow component Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Wyeth (WYE) and Novartis AG (NVS) are expected to report Thursday

[lana2b]

sorry, it's not channeling- it's broke down the trend line on daily and weekly charts
DO your DD
lana

NVS


PFE


STZ


WWW


NVEC

Originally Posted by lana2b

ALL of them in a current uptrend
PFE- healthy profit takien, bouncing off ma50
STZ- basing
WWW-off the support and base and ma 20, no resist ahead good V and little resistance ahead, notice how the volume repeat the PR pattern
NVEC- MA 20 rigth above MA 50, but looks like found support , can be very nice and quick profit
looking at %R may retreate for one day and cont. up
RBN- channeling, off the bottom
GOL- channeling, off the bottom and bounced off ma200
ENH- nice consolidation before next leg up (IMHO)
DVA- channeling, at support and trend line at 55.85, dogi, green candle, dogi-Mmm- not sure, didnt fill the GAP,

GLTO

lana